semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Parkinson Disease Adult individual at least 18 years old 2. Clinical diagnosis Parkinson's Disease 3. Subject has provided informed consent before initiation of any study procedure. 4. Subject has mesenchymal stem cells banked at Hope Biosciences  Clinically significant, uncontrolled cardiovascular, lung, renal, hepatic, or endocrine disease or any other acute or chronic medical condition that, in the opinion of the investigator, may increase the risks associated with study participation. 2. Chemical or ETOH dependency that in the opinion of the investigator would preclude participation in the study 3. Participation in concurrent interventional research studies during this trial 4. Unwillingness to return for follow-up visits
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Parkinson Disease Diagnosis of Parkinson Disease  Inability to walk without physical assistance
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Parkinson Disease Clinical diagnosis of Idiopathic Parkinson's disease Must have acess to internet  Severe cognitive decline Severe visual impairment Severe hearing impairment
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Obesity Age 18-70 Body mass index (BMI) between 25 and 50 kg/m-squared Diagnosis of one or more cardiovascular disease risk factors (prediabetes, type 2 diabetes, hypercholesterolemia, or hypertension) Able to walk 2 city blocks without stopping  Currently participating in another weight loss program Currently taking weight loss medication Lost > 5% of their body weight in the 6 months prior to enrolling Has been pregnant within the 6 months prior to enrolling Plans to become pregnant within 6 months of enrolling Has chest pain during periods of activity or rest, or loss of consciousness in the 12 months prior to enrolling Has any medical condition that would affect the safety of participating in unsupervised physical activity Has history of bariatric surgery Has any condition that would result in inability to follow the study protocol, including terminal illness, substance abuse, eating disorder (not including Binge Eating Disorder) and untreated major psychiatric illness
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Parkinson Disease Upper Extremity Dysfunction Therapy-Related MDS Parkinson's disease diagnostic Classified as I-III on the Hoehn & Yahr motor staging scale Are over 18 years old (above this, without age restriction) Residents in the city of Porto Alegre / RS Have signed an informed consent form  Do not show the understanding of the games on the first day of familiarization Have a cerebral pacemaker implant Have recent injuries or limitations that make the MMSS impossible Do not perform / abstain from two appointments out of the 16 proposed in the intervention protocol, regardless of the group that will be allocated
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Parkinson Disease Parkinson's Disease and Parkinsonism Adult participants (aged 18 years inclusive) Have been diagnosed with PD according to the UK Brain Bank Participants must have demonstrated a positive response to medications to treat the motor symptoms of PD and have been treated with these medications for minimum of three years prior to the screening visit Report limitation to activities of daily living Participants must be able and willing to consent to participate in the study Participants must be willing and able to comply with study requirements Participants and investigators must expect that the participant will be able to remain on a stable regimen of concomitant therapies used for the management of PD motor and non-motor symptoms and not to introduce new medications used to treat motor or non-motor symptoms associated with PD during the trial Participants must have at minimum a moderate burden of NMS Participants must have a study partner (defined as someone who sees the participant for more than one hour a day, 3x per week) that is willing to consent and participate in the trial  Participant anticipates being unable to attend all visits and complete all study activities Women of child-bearing potential who are pregnant or plan to become pregnant during the course of the study trial. Women of child-bearing potential (i.e., are not yet 3 years removed from their first menopausal symptom), who are not abstinent or exclusively in same sex relationships must: 1. Test negative for pregnancy as indicated by a negative urine pregnancy test 2. Agree to use an approved contraception method for the entirety of the trial Have a history or prior diagnosis of dementia Have experienced a myocardial infarction, angina or stroke within the past 12 months Are receiving deep brain stimulation therapy Are treated with a pump for continuous delivery of dopamine replacement medication Use apomorphine rescue Have received MRI guided high intensity focused ultrasound within the past 12 months Experience frequent falls Work night shifts
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Parkinson Disease Parkinson's Disease and Parkinsonism Completion of the study activities in the STEM-PD RCT trial. l Participants must be willing and able to give consent to participate in the study trial  Participant anticipates being unable to attend all visits and complete all study activities in both the RCT and OLE study trial Women of child-bearing potential who are pregnant or plan to become pregnant during the course of the RCT or OLE study trial
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cirrhosis Portal Hypertension Patient with cirrhosis and portal hypertension older than 18 old Patient who underwent a CT scan or MRI in the last 3 months The Mini-Mental State (MMS) test >25 Patient capable of receiving and understanding information relating to the study and of giving his written informed consent Patient affiliated to the French social security system  Cirrhotic patient with overt HE or history of persistent or recurrent HE Hepatocellular carcinoma beyond Milan criteria Portal vein thrombosis Previous transjugular intrahepatic portosystemic shunt (TIPS) or surgical shunt Presence of neurological or psychiatric disorder Patient with treatment by benzodiazepines or opioid substitution Pregnant or nursing women Patient in period of a previous study Patient under guardianship, trusteeship or the protection of justice or incapable of giving their own informed consent
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 50.0-80.0,  Parkinson Disease Mild Cognitive Impairment Aged between 50 to 80 years (inclusive) at time of consent Duration of motor symptoms of at least 1 year Hoehn and Yahr stage between 1 and 3 (inclusive) in ON state Diagnosis of PD according to United Kingdom (UK) Brain Bank Score on Clinical Dementia Rating (CDR) scale = 0.5 Diagnosis of PD-MCI according to MDS PD-MCI, Level I Duration of cognitive impairment of at least 3 months (to distinguish from mild delirium)  Insufficient fluency in English or local language to complete assessments Severe visual or auditory impairment that may interfere with participant's ability to complete assessments Unable to provide informed consent at screening visit Participation in a clinical study involving an investigational drug within 4 months prior to screening Smoking (cigarettes, pipes, cigars, e-cigarettes etc.) or use of smokeless tobacco products (chewing / dipping tobacco, snuff etc.) or anti-smoking nicotine containing products (patches/gum/sprays etc.), within the last 12 weeks HADS depression subscale score ≥ 11 History of deep brain stimulation or other neurosurgical procedure Diagnosis of dementia, including Parkinson's disease dementia (PDD) or Dementia with Lewy Bodies (DLB) Diagnosis of schizophrenia, bipolar disorder or other psychotic disorder Malignant neoplasms within 3 years of screening (except for basal or squamous cell carcinoma of the skin); or had curative surgery/treatment and has been free of malignancy for at least 12 months)
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 45.0-90.0,  Parkinson Disease Diagnosis of Parkinson Disease Previously Untreated or treated for <4 weeks Mild to Moderate Parkinson disease (Hoehn & Yahr Stages I-II) About to start treatment with a L-Dopa preparation (Sinemet)  The presence of other neurologic disease or findings on examination Depression: Geriatric Depression Scale score >11 Use of dopamine agonists or stimulants Evidence of a stroke or mass lesion on prior structural brain imaging (MRI or CT) Evidence of any confounding medical or psychiatric problem that would preclude task participation Participants with cognitive impairment that might impair their capacity to provide informed consent
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Spinal Cord Injuries Adult individual 18 years of age or older. 2. Cognitively intact and capable of giving informed consent. 3. Clinical diagnosis of Traumatic Spinal Cord Injury. 4. Subject has mesenchymal stem cells banked at Hope Biosciences. 5. The patient accepts to receive treatment and to comply with follow-up visits  Clinically significant, uncontrolled cardiovascular, lung, renal, hepatic, or endocrine disease or any other acute or chronic medical condition that, in the opinion of the investigator may increase the risks associated with study participation. 2. Active Alcohol or Drug addiction. 3. Participation in concurrent interventional research studies during this study. 4. Severe organ failure (heart, kidney or liver), confirmed by additional tests or medical history. 5. Unwillingness to return for follow-up visits
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 30.0-85.0,  Parkinson Disease Willing and able to give informed consent Willingness and ability to comply with study requirements PD diagnosis must be confirmed by bradykinesia plus one of the other cardinal signs (resting tremor, rigidity, postural instability) being present Age >30 years Men and women with mild to moderate PD: Hoehn and Yahr scale stages 1 Participants may be on current therapeutic agents (including levodopa, dopamine agonists, anticholinergics, amantadine or selegiline) to treat PD symptoms at the time of enrollment and may remain on these agents throughout the 5-month study period Women of childbearing potential (i.e., those not postmenopausal or surgically sterile) may participate provided that they are using adequate birth control methods for the duration of the study. Women of childbearing potential must have a negative pregnancy test at baseline and be non-lactating  • Subjects with advanced, severe disease, including those with dementia, severe osteoarthritis, allergies, stroke, and visual impairment Presence of atypical PD syndromes due to drugs (e.g., metoclopramide, flunarizine), metabolic identified neurogenetic disorders (e.g., Wilson's disease), encephalitis, or other degenerative diseases (e.g., progressive supranuclear palsy) Any clinically significant medical condition (e.g., active neoplasm, angina) or laboratory abnormality, which would in the judgement of the investigator interfere with the subjects' ability to participate in the study or be followed
Patient description: A 58-year-old African-American woman presents to the ER with episodic pressing/burning anterior chest pain that began two days earlier for the first time in her life. The pain started while she was walking, radiates to the back, and is accompanied by nausea, diaphoresis and mild dyspnea, but is not increased on inspiration. The latest episode of pain ended half an hour prior to her arrival. She is known to have hypertension and obesity. She denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease. She currently takes no medications. Physical examination is normal. The EKG shows nonspecific changes.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Low Back Pain Must live in the United States Must understand and write English Must have access to a computer with e-mail and expect to have this access for at least 3 years Must be 18 years old Must have seen a doctor for back pain at least once in the past year  Pregnancy Back surgery in the past 6 months Expectation of having back surgery in the next 6 months Back pain due to a car accident or other major injury within the last 6 months Back pain or sciatica due to systemic disease (inflammatory rheumatic diseases, tumor, or other) Major physical or mental health condition for which one is currently being treated that severely limits daily activities Terminal illness Receiving disability or workers compensation insurance payments for back pain or sciatica Presently involved in legal proceedings because of back pain or sciatica Difficulty with bladder or bowel control that began with back pain or sciatica
Patient description: A 58-year-old African-American woman presents to the ER with episodic pressing/burning anterior chest pain that began two days earlier for the first time in her life. The pain started while she was walking, radiates to the back, and is accompanied by nausea, diaphoresis and mild dyspnea, but is not increased on inspiration. The latest episode of pain ended half an hour prior to her arrival. She is known to have hypertension and obesity. She denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease. She currently takes no medications. Physical examination is normal. The EKG shows nonspecific changes.

Clinical trial eligibility criteria: eligible ages (years): 30.0-69.0,  Arrhythmia Cardiovascular Diseases Coronary Disease Death, Sudden, Cardiac Heart Diseases Myocardial Infarction Myocardial Ischemia Ventricular Fibrillation Men and women, ages 30 to 69. Documented myocardial infarction
Patient description: A 58-year-old African-American woman presents to the ER with episodic pressing/burning anterior chest pain that began two days earlier for the first time in her life. The pain started while she was walking, radiates to the back, and is accompanied by nausea, diaphoresis and mild dyspnea, but is not increased on inspiration. The latest episode of pain ended half an hour prior to her arrival. She is known to have hypertension and obesity. She denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease. She currently takes no medications. Physical examination is normal. The EKG shows nonspecific changes.

Clinical trial eligibility criteria: eligible ages (years): 25.0-49.0,  Cardiovascular Diseases Heart Diseases Hypertension Obesity Vascular Diseases Men and women, ages 25 to 49. Diastolic blood pressure between 78 and 89 mm Hg. Free of major disease. Not on a special diet or antihypertensive medication at entry. Some mild to moderately obese subjects